JP2012529279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529279A5 JP2012529279A5 JP2012514491A JP2012514491A JP2012529279A5 JP 2012529279 A5 JP2012529279 A5 JP 2012529279A5 JP 2012514491 A JP2012514491 A JP 2012514491A JP 2012514491 A JP2012514491 A JP 2012514491A JP 2012529279 A5 JP2012529279 A5 JP 2012529279A5
- Authority
- JP
- Japan
- Prior art keywords
- linkage
- nucleotides
- phosphorothioate
- nucleotide analogs
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18638809P | 2009-06-12 | 2009-06-12 | |
| US61/186,388 | 2009-06-12 | ||
| US25309009P | 2009-10-20 | 2009-10-20 | |
| US61/253,090 | 2009-10-20 | ||
| PCT/EP2009/067561 WO2010076248A1 (en) | 2008-12-31 | 2009-12-18 | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
| EPPCT/EP2009/067561 | 2009-12-18 | ||
| PCT/EP2010/058278 WO2010142805A1 (en) | 2009-06-12 | 2010-06-14 | New potent anti apob antisense compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529279A JP2012529279A (ja) | 2012-11-22 |
| JP2012529279A5 true JP2012529279A5 (enExample) | 2013-08-01 |
Family
ID=42541569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514491A Pending JP2012529279A (ja) | 2009-06-12 | 2010-06-14 | 新規の強力な抗ａｐｏｂアンチセンス化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9290758B2 (enExample) |
| EP (1) | EP2440215B1 (enExample) |
| JP (1) | JP2012529279A (enExample) |
| CN (1) | CN102802637A (enExample) |
| AU (1) | AU2010258570B2 (enExample) |
| BR (1) | BR112012000214A2 (enExample) |
| CA (1) | CA2764822A1 (enExample) |
| ES (1) | ES2555057T3 (enExample) |
| IL (1) | IL216519A0 (enExample) |
| MX (1) | MX2011013078A (enExample) |
| NZ (1) | NZ596608A (enExample) |
| WO (1) | WO2010142805A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| MX367083B (es) | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). |
| KR20160083876A (ko) * | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| WO2019165067A1 (en) * | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
| TW202031268A (zh) * | 2018-11-13 | 2020-09-01 | 美商雷格勒斯治療公司 | 用於調節mir-10b 活性之微小rna 化合物及方法 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| JP4484702B2 (ja) * | 2002-07-19 | 2010-06-16 | メデラ ホールディング アクチェンゲゼルシャフト | コネクタ装置 |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| CA2518475C (en) * | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| WO2004091515A2 (en) * | 2003-04-09 | 2004-10-28 | Alnylam Pharmaceuticals, Inc. | iRNA CONJUGATES |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| US20060134189A1 (en) * | 2004-11-17 | 2006-06-22 | Protiva Biotherapeutics, Inc | siRNA silencing of apolipoprotein B |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2622583A1 (en) | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| US8470791B2 (en) | 2007-03-22 | 2013-06-25 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
-
2010
- 2010-06-14 WO PCT/EP2010/058278 patent/WO2010142805A1/en not_active Ceased
- 2010-06-14 MX MX2011013078A patent/MX2011013078A/es active IP Right Grant
- 2010-06-14 BR BR112012000214A patent/BR112012000214A2/pt not_active IP Right Cessation
- 2010-06-14 NZ NZ596608A patent/NZ596608A/en not_active IP Right Cessation
- 2010-06-14 JP JP2012514491A patent/JP2012529279A/ja active Pending
- 2010-06-14 ES ES10724511.0T patent/ES2555057T3/es active Active
- 2010-06-14 EP EP10724511.0A patent/EP2440215B1/en not_active Not-in-force
- 2010-06-14 CN CN2010800257913A patent/CN102802637A/zh active Pending
- 2010-06-14 CA CA2764822A patent/CA2764822A1/en not_active Abandoned
- 2010-06-14 US US13/140,777 patent/US9290758B2/en not_active Expired - Fee Related
- 2010-06-14 AU AU2010258570A patent/AU2010258570B2/en not_active Ceased
-
2011
- 2011-11-22 IL IL216519A patent/IL216519A0/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011139695A3 (en) | Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom | |
| WO2011139699A3 (en) | 5' modified nucleosides and oligomeric compounds prepared therefrom | |
| FR2936102B1 (fr) | Procede de preparation d'un materiau composite silicium/ carbone, materiau ainsi prepare et electrode notamment electrode negative, comprenant ce materiau. | |
| WO2010048552A3 (en) | Methods of using oligomeric compounds comprising 2'-substituted nucleosides | |
| JP2009504138A5 (enExample) | ||
| WO2010009478A3 (en) | Compositions and methods for treating disorders associated with overweight animals | |
| WO2006110607A8 (en) | Methods for treating infectious disease exacerbated asthma | |
| WO2010135836A8 (en) | Novel beta-glucosidase enzymes | |
| WO2012166471A3 (en) | Hydrocarbon transformations using carbocatalysts | |
| WO2008108830A8 (en) | Immunogenic and therapeutic compositions for streptococcus pyogenes | |
| WO2009114089A3 (en) | Using fullerenes to enhance and stimulate hair growth | |
| WO2009099877A3 (en) | Closterovirus vectors and methods | |
| WO2010046493A3 (en) | Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same | |
| FR2937566B1 (fr) | Catalyseur d'hydrogenation, notamment de sulfure de carbone | |
| WO2012090194A3 (en) | Compositions and methods for treating a skin disorder | |
| WO2009150374A3 (fr) | Fibres a conductivite electrique pour systemes bioelectrochimiques, electrodes realisees avec de telles fibres et systemes comportant une ou plusieurs de telles electrodes | |
| ATE536360T1 (de) | Neues nukleinsäuretransfersystem | |
| Nguyen | Some new constructions of strength 3 mixed orthogonal arrays | |
| WO2009027527A3 (en) | Rna antagonist compounds for the modulation of fabp4/ap2 | |
| Banerjee et al. | Population differentiation in dromedarian camel: a comparative study of camel inhabiting extremes of geographical distribution | |
| WO2015044890A3 (en) | Tools and methods using mirna 182, 96 and/or 183 for treating pathologies | |
| Larsen | Apply project management concepts to R&D | |
| Dikranjan et al. | Locally compact abelian groups admitting non-trivial quasi-convex null sequences | |
| 胡泳 | Web 2.0 | |
| WO2011005363A3 (en) | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |